TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04283942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (ICR)
Description: Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided.
Study: NCT04283942

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuous calorie restriction (CCR)
Description: Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided.
Study: NCT00937404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix
Description: All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
Study: NCT01638052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine + Clonidine
Description: Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
Study: NCT00230282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 3 to 30 mg, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: \[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: (RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
Study: NCT00990327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
Study: NCT02867618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
Study: NCT01893372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 200 mg by mouth daily in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 200 mg by mouth daily in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypomethylating Agent (HMA)
Description: The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
Study: NCT02956759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pan-retinal photocoagulation laser treatment
Description: PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pan-retinal photocoagulation laser treatment
Description: PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
Study: NCT02703870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: verum tDCS
Description: real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: verum tDCS
Description: real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
Study: NCT01720992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A theory-based action planning toolkit
Description: The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).

Intervention type: OTHER
Group type: OTHER
Intervention: A theory-based action planning toolkit
Description: The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
Study: NCT01522989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
Study: NCT00662610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 375 mg -750 mg -1125 mg bid
Description: naproxcinod 375 mg -750 mg -1125 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 250 mg - 500mg -750 mg bid
Description: naproxen 250 mg - 500mg -750 mg bid
Study: NCT03096054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3143921 hydrate
Description: LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3143921 hydrate
Description: LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
Study: NCT01685931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
Study: NCT02105792

Intervention type: DRUG
Intervention: second- or third-line glucose-lowering diabetes treatment
Description: Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
Study: NCT00785395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Description: Up-down dosing determination
Study: NCT04204954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea Tree Oil Shampoo
Description: Twice a day eyelid margin cleansing for three days.

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin Ophthalmic Ointment 0.3%
Description: Applied topically in the eyelid margin every four hours for three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin Ophthalmic Ointment 0.3%
Description: Applied topically in the eyelid margin every four hours for three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin Ophthalmic Ointment 0.3%
Description: Applied topically in the eyelid margin every four hours for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Ophthalmic Ointment 0.3%
Description: Applied topically in the eyelid margin every four hours for three days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baby shampoo
Description: Twice a day eyelid margin cleansing for three days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blephaclean
Description: Twice a day eyelid margin cleansing for three days.
Study: NCT03940664

Intervention type: OTHER
Intervention: immunohistochemistry on Formalin fixed and paraffin embedded blocks

Intervention type: OTHER
Intervention: immunohistochemistry on Formalin fixed and paraffin embedded blocks
Study: NCT00588848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoadjusting CPAP (VPAP Auto)
Description: An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
Study: NCT02187484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277
Study: NCT06278584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iLUX Treatment System
Description: Local heat using an electrical warming mask for 5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iLUX Treatment System
Description: Local heat using an electrical warming mask for 5 minutes.
Study: NCT01562964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Description: Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
Study: NCT04190485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMNL-143 Probiotic Toothpastes
Description: Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMNL-464 Probiotic Toothpastes
Description: Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
Study: NCT01606098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of the primary tumour
Description: Surgical resection of the colon tumour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic treatment
Description: First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic treatment
Description: First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)
Study: NCT02469025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual caudal traction mobilization in resting position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual caudal traction mobilization in end range position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selftreatment
Description: Each subject is advice to do some exercises at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selftreatment
Description: Each subject is advice to do some exercises at home
Study: NCT05919732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexmedetomidine, Caffeine, Tylenol
Description: bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, rocuronium, caffeine, Tylenol, bupivacaine
Description: propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)
Study: NCT00630500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Tablets, 5 or 10 mg, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets corresponding to 5 or 10 mg, twice daily, 6 months
Study: NCT03250793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer
Description: While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
Study: NCT02941692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Oxytocin
Study: NCT02113449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Description: Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
Study: NCT02662205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy Group
Description: Traditional process group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga class
Description: Yin yoga class

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy Group
Description: Yoga psychotherapy group integrating yoga and process dialogue
Study: NCT02346357

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obturator Nerve Block
Description: Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Obturator Nerve Block
Description: Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT00119002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 1mg/kg dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mg/kg placebo
Study: NCT00068549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo whole pelvis radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study: NCT03928509

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01657149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic massage and individual physiotherapy
Description: lymphatic massage and individual physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: individual physiotherapy only
Description: individual physiotherapy only
Study: NCT03971227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuity 200 (Fluoroxyfocon A) contact lens
Description: Daily wear rigid gas permeable contact lens
Study: NCT02703870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS
Description: sham transcranial direct current stimulation, 10 sessions, for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham transcranial direct current stimulation, 10 sessions, for 20 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VRT
Description: Vision restoration training, 10 sessions, 20 minutes

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: VRT
Description: Vision restoration training, 10 sessions, 20 minutes
Study: NCT00774150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 16 sessions of CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Client Centered Therapy
Description: 16 sessions of CCT
Study: NCT02346357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline